ACTU — Actuate Therapeutics Balance Sheet
0.000.00%
- $174.81m
- $166.57m
Annual balance sheet for Actuate Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|
Period Length: | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Cash and Equivalents | |||
Cash and Short Term Investments | 20.4 | 2.96 | 8.64 |
Prepaid Expenses | |||
Total Current Assets | 20.5 | 3 | 9.21 |
Other Long Term Assets | |||
Total Assets | 20.5 | 3 | 9.32 |
Accounts Payable | |||
Accrued Expenses | |||
Notes Payable / Short Term Debt | |||
Total Current Liabilities | 4.34 | 6.92 | 8.8 |
Long Term Debt | |||
Total Long Term Debt | |||
Total Debt | |||
Total Other Liabilities | |||
Total Liabilities | 5.65 | 8.44 | 9.21 |
Redeemable Preferred Stock | |||
Non Redeemable Preferred Stock | |||
Common Stock | |||
Additional Paid In Capital | |||
Retained Earnings (Accumulated Deficit) | |||
Total Equity | 14.8 | -5.45 | 0.104 |
Total Liabilities & Shareholders' Equity | 20.5 | 3 | 9.32 |
Total Common Shares Outstanding | |||
Total Preferred Shares Outstanding |